Cantor Fitzgerald Initiates Coverage On LifeMD with Overweight Rating, Announces Price Target of $7
Portfolio Pulse from richadhand@benzinga.com
Cantor Fitzgerald analyst Sarah James has initiated coverage on LifeMD (NASDAQ:LFMD) with an Overweight rating and a price target of $7.
July 21, 2023 | 10:53 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
LifeMD has been given an Overweight rating by Cantor Fitzgerald, with a price target of $7.
The Overweight rating from Cantor Fitzgerald indicates a positive outlook for LifeMD. The price target of $7 suggests that the analyst believes there is potential for the stock's price to increase. This could lead to increased investor interest and potentially a rise in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100